Sage Journals: Discover world-class research

Abstract

Urological cancers, such as prostate cancer (PC), bladder cancer (BC), renal cell carcinoma (RCC), and testicular cancer (TC), are major causes of morbidity and mortality. Effective therapies depend on factors such as cancer type, stage, grade, the individual's overall health, and treatment priority. Currently, treatment options include surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy, but these approaches often face challenges including treatment resistance, disease recurrence, cytotoxicity, and severe complications. Natural products have emerged as promising sources for new drug development, and resveratrol, a natural polyphenolic compound found in berries, nuts, red wine, and grapes, has garnered significant interest. Resveratrol exhibits a range of biological effects such as anti-inflammatory, antiviral, antioxidative, antiproliferative, and anti-angiogenic activities. Results of this study highlights evidence that resveratrol can inhibit tumor cell proliferation, induce apoptosis, and suppress metastasis in various urological cancers. Moreover, it modulates key molecular pathways implicated in cancer progression, including PI3K/Akt, NF-κB, and STAT3 signaling. These findings suggest that resveratrol holds potential as an adjunctive therapeutic agent for urological cancers, though further clinical studies are warranted to confirm its efficacy and optimize its clinical application. This literature review has been performed to discuss the possible anticancer effects and mechanisms of resveratrol in relation to urological cancers, with a focus on PC, BC, RCC, and TC.

Keywords

prostate cancer Bladder cancer Renal cell carcinoma Testicular cancer Resveratrol Chemotherapy Natural compounds Drug resistance Nanoformulations

Introduction

Urological system-related health problems have become progressively common around the world and influence subjects in a broad range of ages.^1,2 Urological cancers, like prostate cancer (PC), bladder cancer (BC), renal cell carcinoma (RCC), and testicular cancer (TC), are associated with increasing morbidity and mortality rates per year.³ In 2021, over 400,000 newly identified cancer cases and over 66,000 cancer-related death cases were attributed to urological malignancies in the United States.⁴ Some factors increase the risk of occurrence of this type of cancer, for instance, chronic irritation, exposure to chemical and environmental (particularly cigarette smoking), aging (especially subjects in the range of 50-70 years), and genetic deviations, for instance, dysregulation of TP53, TP63, RB1, EGFR genes and Ras and p21 proteins.⁵ The standard therapeutic approaches for urological cancers are determined by multiple factors, including type, stage, grade of cancer, individual's overall health status, and treatment priority. Conventional therapies for these urological neoplasms comprise surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy.^6–8 Unfortunately, these therapeutic methods face some challenges, such as the risk of treatment resistance and disease recurrence, cytotoxicity, and incidence of rigorous complications.⁹ Finding and harnessing novel therapeutic strategies is important for urological cancers.⁵ One of the key sources in drug design and development is natural compounds.¹⁰ For decades, humans have recognized natural herbal formulations for maintaining health, preventing diseases, and supporting physical and mental health. The increasing usage of natural compounds originates from their high acceptability, better safety profile with fewer side effects, effective multi-faceted biological actions, and economic affordability. The sum of these characteristics make natural compounds promising alternatives in medicine, cosmetics, and food industries.^11,12 In this regard, resveratrol (35,4′-trihydroxy-trans-stilbene), a polyphenolic compound found in various foods including berries, nuts, wine, and grapes, has demonstrated significant potential to improve a wide range of conditions such as cardiovascular diseases, neurological disorders, diabetes, infertility, and more.^13–16 This compound has also been found to exert diverse biological and pharmacological beneficial influences, such as anti-inflammatory, antiviral, and antioxidative, as well as anticancer, antiproliferative, and anti-angiogenic activities in different cancers.¹⁷ From a molecular viewpoint, the structure of resveratrol consists of two phenolic rings with para-hydroxyl and ortho double hydroxyl groups linked by a double bond.¹¹ In recent years, several documents accentuated urological cancer therapy by this natural compound through various molecular and cellular mechanisms.^17–19 Hence, this literature review aims to recapitulate evidence regarding the anticancer potential of resveratrol for improving urological cancers with a mechanistic focus.

Search Strategy

In this narrative review, related documents with the status of “In press” and “Published” in the English language have been evaluated qualitatively. The inclusion criteria were papers (original and review articles) focusing on the functionality of resveratrol in urological cancers, comprising prostate cancer, bladder cancer, renal cell carcinoma, and testicular cancer, preclinically (in vitro and in vivo) or clinically. Papers that lacked relevance to the purpose of the study, not peer-reviewed, or provided inadequate information were excluded. The used keywords include “Resveratrol,” “Prostate cancer,” “Bladder cancer,” “Renal cell carcinoma,” and “Testicular cancer” in different databases like Google Scholar, Scopus, PubMed, Web of Science, and Scientific Information Databases from 2007 until 1 March 2025.

Resveratrol and Prostate Cancer

PC is ranked the second most common malignancy and the fifth underlying reason for cancer-related death in men populations globally.²⁰ In the United States, 268,490 newly identified subjects with PC and 34,500 death cases as a result of this disease were reported in 2022.^21,22 Using standard therapies for patients with PC is along with several challenges, like resistance to treatment and side effects. So, there is an indispensable need for finding alternative methods to solve these problems.²³ Several papers have reported the potential role of natural polyphenols, including resveratrol (Table 1), in treating prostate neoplasms in experimental investigations.^24–27 As an example, in the study of Wang et al, the anti-PC effects of resveratrol at different concentrations were investigated in vitro and in vivo. The in vitro assessment was performed by exposing PC cell lines (LNCaP cells) to a medium comprising FBS (10%) with different doses of resveratrol (0, 1, 5, and 25 μM). The reports of RT–PCR and Microarray analyses showed the downregulation of kallikrein 3 (PSA), upregulation of BCHE (downregulated by androgen), stimulation of CDKN1A, as a cyclin suppressor orchestrated by p53, as well as the attenuation of expression of FRAP1–mTOR and IGF-1R mRNAs (androgen-associated mRNAs). Also, the in vivo results of this work revealed that this phytochemical (50 and 100 mg diet) could suppress cancer cell growth in a nude mouse xenograft model of LNCaP cells probably by regulating both estrogen and androgen-related occurrences.²⁸ Another preclinical project studied the function of resveratrol as a radiosensitizer agent by affecting cancer stem cells in PC cells, PC-3, resistance to radiation therapy by tracing the markers of EMT (E-cadherin and Vimentin) and stem cells (DCLK1, CXCR4, OCT4, SOX2, CD29, CD49b, and CD44).²⁹ Cancer stem cells are a small population of cells in tumors with the ability of self-renovation and differentiation into diverse lineages that theoretically construct the foundation of tumor development, metastasis, and therapy resistance.³⁰ The results of the mentioned research team suggested that resveratrol administration could reduce cancer cell survival and abate stem cell and EMT markers at different doses (35-140 µM) in vitro.²⁹ Other experimental investigations have suggested resveratrol in PC therapy in light of its various cellular and molecular therapeutic mechanisms, such as inhibiting angiogenesis by attenuating vascular endothelial growth factor (VEGF), decreasing or suppressing the levels of matrix metalloproteinases (MMPs) and tumor necrosis factor receptor-associated factor 6 (TRAF6) and hedgehog (HH) signals, suppressing the Akt radio-resistance pathway, boosting the tumor suppressor AMPK, downregulating oncogenic microRNAs (the clusters of miR-106ab and miR-17-92), and upregulating tumor suppressor microRNAs (eg, miR-1290, miR-149, miR-1908, miR1268, and miR-575) as demonstrated in literature and Figure 1.^24,31,32 Papers have also shown that resveratrol analogues can be effective in the treatment of PC. Regarding this issue, an experimental study evaluated the anti-tumor capacity of resveratrol and its analogues (piceatannol and trimethoxy-resveratrol) using cell proliferation and colony formation assays in vitro and in vivo.³³ In the end, it was observed that trimethoxy-resveratrol, whose increased tissue and serum accumulation was demonstrated, is the most active compound in suppressing cell proliferation in vitro. Besides, pretreatment with the resveratrol and its analogues (for two weeks) reduced tumor volume and cell growth and colonization and suppressed the secretion of inflammatory cytokine IL-6 in a xenograft mouse model of PC. Intriguingly, both two analogues of resveratrol showed their inhibition of tumor progression, which was better than resveratrol.³³ Together with the beneficial effects of resveratrol and its analogues, there is promising news regarding the anti-carcinoma impacts of nano-based formulations of resveratrol for prostate malignancy. In a scientific attempt, Singh and co-workers applied a receptor-based targeted delivery method by ball-milled nanoparticles (PBMNPs) conjugated with folic acid (FA) for loading resveratrol or a combination of docetaxel and resveratrol to treat PC in vitro.³⁴ The findings resolved that neither resveratrol nor docetaxel can give rise to remarked suppression of PC cells (NCaP, C4-2 B, and PC3) resistant to drugs. On the contrary, the utilization of conjugated PBMNPs for encapsulating both resveratrol and docetaxel not only improved the bioavailability of these two drugs but also abrogated multidrug resistance (MDR) and dramatically suppressed cell growth. The Flow cytometry results revealed a considerable elevation in the apoptotic cell number by 30.92% and 65.9% in the conjugated nanoformulations loaded with resveratrol and the combination of resveratrol and docetaxel, respectively. In addition, the expressions of COX-2 (an inflammatory marker), NF-kB p65 (a cell survival marker), and anti-apoptotic genes (Bcl-xL, Survivin, and Bcl-2) were significantly lowered, but the expressions of pro-apoptotic genes (Bak and Bax) were increased following cancer therapy with nano-based formulation of two combined drugs.³⁴ Another anticancer choice for targeted delivery of resveratrol can be mesoporous silica nanoparticles (MSNs), which are considered a suitable drug delivery platform in light of their flexibility and high capacity to load drugs.³⁵ In this line, Chaudhary and colleagues loaded resveratrol onto amine and phosphonate-modified MSNs (∼60 nm) to potentiate its antiproliferative activity against PC cells (PC3 cell line). MSNs modified with the phosphonate group dramatically promoted the antiproliferative capacity of resveratrol (IC50 = 7.15 μM) compared with free resveratrol (IC50 = 14.86 μM). However, MSNs modified with the amine group didn't influence cancer cell proliferation despite having IC50 value more than free resveratrol (IC50 = 20.45 μM).³⁵ Overall, these data highlight the pivotal role of resveratrol in attenuating PC cell survival, proliferation, growth, migration, invasion, and metastasis through different mechanisms. Also, it seems that the analogues and nanoformulations of resveratrol can be better strategies for PC treatment; however, further research work in preclinical and clinical studies are to be undertaken to confirm these results.

Figure 1.

Anti-Cancer Mechanisms of Resveratrol Against Prostate Cancer.

Table 1.

In Vitro and in Vivo Studies of Resveratrol and Prostate Cancer.

Resveratrol or its analogues/nano-based formulations	Resveratrol dose/concentration	Target (s)	Effect/mechanism (s)	Species	Cell line	Ref.
Resveratrol	50-100 mg/kg and 0-25 µM	PSA, BCHE, FOX3A, FRAP, PIK3R3, IGF-1R, STK39, and CDKN1A	Postponing tumor growth, increasing angiogenesis, and suppressing apoptosis	Athymic nude mice	LNCaP	²⁸
Resveratrol	0-30 µM	PSA, AR, p21, p27, cyclin A, cyclin E, and CDK2	Suppressing DNA synthesis	-	LNCaP and DU145	³⁶
Resveratrol	35, 70, and 140 µM	CD29, CD49b, CD44, DCLK1, OCT4, SOX2, CXCR4, Vimentin, and E-cadherin	Reducing cell viability and repressing EMT	-	PC-3	³⁷
Resveratrol	0-40 µM	MMP-2, VE-cadherin, EphA2, and Akt	Repressing cell invasion and the formation of vasculogenic mimicry tube	-	PC-3 and DU145	³⁸
Resveratrol	625 mg/kg	IGF-1, p-ERK1/2, and AR	Reducing cell proliferation	Male C57BL/6 mice	-	³⁹
Resveratrol	50, 100, and 200 µg/mL	AR, Gk11, cleaved caspase-3 and -7, cyclin D1, and Bcl-xL	Repressing cell growth, stimulating apoptosis, and reducing the development of neoplastic lesions	Male heterozygous TRAP	-	⁴⁰
Resveratrol	0-150 μM	Cyclin D1, cyclin E, cyclin B1, CDK1, p53, p27, p21, caspase-8 and -9, Bax, and Bcl-2	Stimulating apoptosis, arresting cell cycle, and repressing cell growth	-	LNCaP and PC-3	⁴¹
Resveratrol	20 µM	mTOR, Akt, PI3K, FOXO, TRAIL, Bim, DR4, and DR5	Stimulating apoptosis	-	LNCaP	⁴²
Resveratrol	0-50 μM	E-cadherin, Vimentin, and Gli1	Reversing EMT, repressing cell invasion, and decreasing cell proliferation	-	LNCaP and PC-3	⁴³
Resveratrol	50 μM	p21, p53, p15, cyclin B, CDK2, cyclin D, TRAILR1, and Fas	Repressing cell proliferation and enhancing apoptosis and cell senescence	-	PC-3	⁴⁴
Resveratrol	0-75 μM	TRAF6, NF-κB, SLUG, Vimentin, and E-cadherin	Repressing cell proliferation and migration	-	PC-3 and DU145	⁴⁵
Resveratrol	25 μM	p21, CDK4, and cyclin D1	Inhibiting cell growth and arresting cell cycle	-	WPE1-NB26, WPE1-NB14, WPE1-NA22, and RWPE-1	⁴⁶
Resveratrol	25 μM	PCAT29, STAT3, IL-6, PDCD4, and miR-21	Reducing cell viability and proliferation	-	LNCaP and DU145	⁴⁷
Resveratrol	10 µM	HIF-1	Postponing cell growth	-	PC-3 and LNCaP	⁴⁸
Resveratrol	0-100 µM	ARV7	Repressing cell growth		PC-3	⁴⁹
Resveratrol	1-100 μM	AR and PSA	Repressing cell proliferation and growth	-	LNCaP, Du145, and PC-3	⁵⁰
Resveratrol	0-200 μM	DDX5 and mTORC1	Stimulating apoptosis and repressing cell growth	-	DU145 and PC-3	⁵¹
Resveratrol	25-100 µM	PSA, AR, Akt, and ARV7	Repressing cell proliferation and stimulating apoptosis	-	LNCaP	⁵²
Resveratrol	0-50 µM	COX-2, pSer-15-p53, and pERK1/2	Repressing cell proliferation	-	LNCaP	⁵³
Resveratrol	0-100 µM	mTOR, Akt, CHOP, GRP78, LC3B-II, and STIM1	Stimulating autophagy, repressing cell proliferation and viability, and inducing endoplasmic reticulum stress	-	DU145 and PC-3	⁵⁴
Resveratrol analogue HS-1793	25-100 μM	VEGF, HIF-1α, PI3K, and Akt	Repressing cell migration	-	PC-3	⁵⁵
Resveratrol and its combination with ionizing radiation	5 mg/kg and 0-1000 μg/mL	p-γ-H2AX, p- CHK2, p- ATM, p-p53, caspase-3, and PARP	Inducing cell death, repressing cell proliferation, decreasing cell viability, elevating radiosensitivity, and suppressing tumor growth	Male nude mice	PC3-KD and LAPC4-KD	⁵⁶
Pure resveratrol and resveratrol encapsulated in liposome	50 mg/kg and 10 μM	Cyclin D1, AR, mTOR, and p-Akt	Deceasing body wight, repressing cell growth, and stimulating apoptosis	Male B6C3F1/J mice	PTEN-Cap8	⁵⁷
Resveratrol encapsulated in polymeric nanoparticles	0-50 μM	Caspase-3	Decreasing cell viability and stimulating apoptosis	-	LNCaP	⁵⁸
Resveratrol and Docetaxel co-delivery by PEGylated nano-liposomes	5.65 mg/kg and 18.3 μg/mL	Caspase-3	Repressing tumor growth and stimulating apoptosis	Balb/c nude mice	DU145 and PC-3	⁵⁹
Resveratrol loaded onto surface modified mesoporous silica nanoparticles	10, 15, and 20 µM	-	Repressing cell proliferation and decreasing cell viability	-	PC-3	³⁵
Planetary ball milled nanoparticle loaded with resveratrol	3 μM	Caspase-3, Bak, Bax, Bcl-2, Bcl-xL, Survivin, MDR-1, MRP-1, ABCG2, COX-2, and NF-kB p65	Inducing apoptosis and reducing cell proliferation	-	PC-3, LNCaP, and C4-2 B	⁶⁰
Resveratrol nano formulation	_	ROS, NF-kB p65	Increase of apoptosis and Inhibition of abnormal NF-kB	_	PC3	⁶¹
Resveratrol	4.4 μg	_	Increase of prostate specific antigen doubling time (PSADT), reduction of cancer cells aggression and the risk of metastasis	_	PC3	⁶²

Resveratrol and Bladder Cancer

Bladder cancer (BC), is the most frequent malignancy of the urinary system, and is the fourth most common cancer in men and 11th in women.^63,64 BC is mainly classified into nonmuscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC).⁶⁵ For this cancer, different therapies (eg, radical cystectomy, radiotherapy, and chemotherapy) have been offered; however, these cancerous cells have the capacity to resist treatments.⁶⁶ Fortunately, several preclinical papers have shown that using natural-based products, especially resveratrol, can pave the way for treating BC.⁶⁷ In this line, researchers have focused on a lot of therapeutic processes of resveratrol against this common type of urinary system cancer (Table 2). For instance, Wang et al deliberated on the effects of resveratrol (0-350 µM) and other natural compounds (epigallocatechin gallate and ginsenoside Rh2) on multidrug resistance (MDR), a main obstacle for successful cancer therapy, in human BC cells (pumc-91) resistant to adriamycin (ADM) in vitro by assessing the protein and mRNA expression levels of drug resistance-related proteins, comprising topoisomerase-II (Topo-II), B cell leukemia/lymphoma-2 (Bcl-2), glutathione S-transferase (GST), lung resistance protein (LRP), and multidrug resistance protein 1 (MRP1) by immunofluorescence and reverse transcription-quantitative polymerase chain reaction assays, respectively.⁶⁸ This study revealed the reversing role of resveratrol in drug resistance in BC, as evidenced by a remarked reduction of Bcl-2, GST, LRP, and MRP1 levels and the elevation of Topo-II levels in comparison with the control group.⁶⁸ Anti-apoptotic influences of Bcl-2 protein have a key role in MDR, and GST develops drug resistance through direct detoxification.^69,70 LRP is involved in drug resistance by extruding drugs from the nucleus to the cytoplasm by vesicular trafficking; also, MRP1, as an efflux pump, expels different anticancer drugs from the desired cancer cells.^71–73 On the other hand, the decreased sensitivity and function of Topo-II are important for drug resistance promotion.⁷⁴ Other findings of this research addressed cell cycle arrest at the S phase along with a reduction in the number of cells at the G1 phase and cell growth suppression upon resveratrol therapy.⁶⁸ Almeida et al explored toxicogenomic and antiproliferative aspects of resveratrol (12.5-250 μM) in BC cells with diverse TP53 status (grade1, p53 wild-type RT4; 5637-grade 2 and T24-grade 3, TP53 mutated) in vitro.⁷⁵ In this work, resveratrol stimulated DNA damage and reduced cell proliferation in BC cells. Concerning the long-term influences, resveratrol could decrease colony formation of BC cell lines. TP53 wild-type cells underwent considerable apoptosis together with the downregulation of SRC, mTOR, and Akt. The antiproliferative effects of resveratrol on wild-type TP53 cells were along with DNMT1 gene regulation. Also, there was a cell cycle arrest at the S phase with downregulation of the PLK1 gene in the TP53 mutated cells. Moreover, nuclear PCNA attenuation and HOXB3/RASSF1A pathway regulation were reported in BC cells in the highest grade.⁷⁵ RASSF1A, as a tumor suppressor, is silenced through its promoter region hypermethylation in a wide spectrum of cancers, such as BC.⁷⁶ RASSF1A suppression takes place through the oncogene HOXB3, stimulating the expression of the DNMT3B gene encoding the enzymes that have a substantial role in DNA methylation.⁷⁷ In an in vitro (T24 cell lines) and in vivo (male BALB/c-nude mice) investigation, the chemopreventive capacity of resveratrol against BC at doses of 0-250 μM and 20 mg/kg, respectively, was scrutinized.⁷⁸ From a more exact view, the in vitro findings addressed apoptosis induction by regulating Bcl-2 family proteins and triggering caspase-3 and −9 and subsequently degrading poly(ADP-ribose) polymerase (PARP). Furthermore, resveratrol therapy caused cell cycle arrest at the G1 phase in T24 cells by downregulating cyclin-dependent kinase 4 (CDK4), cyclin D1, and phosphorylated Rb and activating p21. This natural product also suppressed Akt phosphorylation, while p38 MAPK phosphorylation was promoted. The in vivo outcomes reflected tumor growth suppression, possibly by reducing the expression of fibroblast growth factor-2 (FGF-2) and VEGF.⁷⁸ In another in vitro and in vivo research performed by Wu et al, the cell line model was established by exposing human TCC EJ cells to 100-200 µM resveratrol to imitate intravesical drug injection. The analyzed data exhibited that the administration of 150 or 200 µM resveratrol (for 2 h) causes remarked apoptosis and cell cycle arrest at the S phase along with decreased phosphorylation, nuclear translocation, and transcription of STAT3 (Figure 2), the attenuated expression of VEGF, c-Myc, cyclinD1, and Survivin (STAT3 downstream genes), and nuclear translocations of p53 and Sirt1. In the mentioned work, an orthotopic nude mouse model was designed through the injection of EJ cells into the sub-urothelial layer, and then 50 µl of 200 µM resveratrol was administrated; consequently, similar findings were reported.⁷⁹ In a distinct study, structure-function association and metabolic status of resveratrol (trans-resveratrol) and its analogues (acetyl resveratrol, oxyresveratrol, and polydatin) in human BC cells (T24 cells) were examined to suggest a suitable formulation of resveratrol with enhanced bioavailability to fight this cancer.⁸⁰ To appraise the influences of resveratrol and its analogues on BC viability, T24 cells were exposed to various concentrations of drugs (0-200 μmol·L⁻¹). Finally, the outcomes of the MTT test demonstrated that, except for polydatin, with elevating concentrations of drugs at certain time points, resveratrol, oxyresveratrol, and acetyl resveratrol suppress cell growth in a time- and dose-dependent approach (oxyresveratrol > acetyl resveratrol > resveratrol > polydatin). The next step in this project was to investigate the effects of these compounds on apoptosis. In this respect, it was unveiled that resveratrol, oxyresveratrol, and acetyl resveratrol can stimulate this type of programmed cell death in T24 cells; however, polydatin did not reflect the apparent apoptosis-stimulating influence on T24 cells. HRMS, LC-MS/MS, and HPLC analyses revealed that resveratrol is the main metabolite during the metabolic occurrence of acetyl resveratrol. Furthermore, resveratrol concentration in acetyl resveratrol-incubated T24 cell lysate was increased compared with the resveratrol-incubated group, showing the better absorption of acetyl resveratrol and the protective role of acetyl groups for the phenolic hydroxyl groups from glucuronidation or sulfation, and eventually its good bioavailability and biopotency.⁸⁰ Overall, it seems that resveratrol can be useful in BC therapy by targeting molecular and cellular occurrences, like stimulating apoptosis, elevating oxidative stress, and reducing ATP concentration, as well as reversing drug resistance. Besides, the analogues and nano-based carriers of resveratrol can be suitable formulations for this therapeutic purpose.

Figure 2.

Anti-Cancer Mechanisms of Resveratrol Against Bladder Cancer.

Table 2.

In vitro and in vivo Studies of Resveratrol and Bladder Cancer.

Resveratrol or its analogues/nano-based formulations	Resveratrol dose/concentration	Target (s)	Effect (s)	Species	Cell line	Ref.
Resveratrol	0.1-100 µM	Bcl-2, Bad, NO, and PGE₂	Stimulating cell death and decreasing cell growth (at high concentrations)	-	ECV304	⁸¹
Resveratrol	20 mg/kg and 0-200 µM	p21, cyclin D1, CDK4, phosphorylated Rb, Akt, p38 MAPK, VEGF, FGF-2, Bcl-xL, Bcl-2, Bad, caspase-3, and PARP	Stimulating apoptosis and decreasing tumor growth	Nude mice	T24	⁷⁸
Resveratrol	50 µl of 200 µM and 100-200 µM	STAT3, VEGF, c-Myc, cyclinD1, Survivin, p53, and Sirt1	Stimulating apoptosis, arresting cell cycle, and repressing cell and tumor growth	Nude mice	EJ	⁷⁹
Resveratrol	0-350 µM	Bcl-2, GST, LRP, and MRP1	Reversing drug resistance, arresting cell cycle, and repressing cell growth	-	Pumc-91/ADM	⁶⁸
Resveratrol	12.5-250 μM	SRC, mTOR, Akt, DNMT1, RASSF1A, HOXB3, and PLK1	Reducing cell proliferation and stimulating DNA damage and apoptosis	-	T24, 5637, and RT4	⁷⁵
Resveratrol	0-50 μM	miR-21, Bcl-2, Akt, and caspase-3	Stimulating apoptosis and cytotoxicity	-	5637 and T24	⁸²
Resveratrol	0-50 µM	MMP-2 and -9, ERK1/2, and JNK1/2	Repressing cell invasion, migration, and adhesion	-	T24	⁸³
Resveratrol	12.5-200 μM	SMAD4, CDH1, and CTNNB1P1	Elevating ROS formation, repressing cell migration, and decreasing cell viability and proliferation	-	T24, 5637, and RT4	¹⁸
Resveratrol	2.5-100 mmol/L	Cytochrome c and caspase-3 and -9	Stimulating apoptosis, reducing cell viability, disrupting mitochondrial membrane potential, elevating ROS formation, and decreasing ATP concentration	-	T24 and BTT739	⁸⁴
Resveratrol and its analogs including acetylresveratrol, xyresveratrol, and polydatin	0-200 µM	-	Exerting considerable morphological changes and apoptotic and inhibitive effects except polydatin	-	T24	⁸⁰
Combination of resveratrol and rapamycin	100 µM	PDCD4, p-S6K1, p-mTOR, p-S6, p-4EBP, p-eIF4B, p-Akt, PRAS40, capase-3, PARP, mcl-1, and surviving	Stimulating apoptosis and repressing cell survival, migration, and growth	-	639 V, MGH-U1, and HCV29	⁸⁵
Combination of resveratrol and Doxorubicin	150-250 µM	-	Reducing cell migration and increasing ROS	-	T24 and 5637	⁸⁶
Nanoemulsion loaded with resveratrol	25 and 50 µM	-	Inducing oxidative stress and decreasing cell viability	-	T24	⁸⁷

Resveratrol and Renal Cell Carcinoma

After prostate and bladder cancers, renal cell carcinoma (RCC), the most common cancer of the kidney, is ranked the third most prevalent cancer among urologic malignancies.^88,89 RCC is mainly divided into several subtypes comprising papillary RCC types 1 and 2, clear cell RCC, mixed oncocytoma, or chromophobe RCC.⁹⁰ Dissimilar to other malignancies, there are insufficient prognoses and biomarkers for RCC,^91,92 and RCC cases show resistance to conventional treatments, such as chemotherapy and radiation therapy.^93,94 Thus, finding novel therapeutic agents and potentials remains a priority for RCC treatment.⁹⁵ In recent years, multiple studies have been accomplished to evaluate the therapeutic effects of resveratrol against RCC in vitro and in vivo (Table 3).^96,97 In an in vitro study performed by Kim et al on RCC cell lines, 786-O and Caki-1 cell lines, it was approved that resveratrol suppresses the phosphorylation and activation of STAT3 and STAT5, which are related to the inhibition of the upstream kinases (namely, c-Src and JAK1/2), in a concentration-dependent manner.⁹⁸ STAT proteins, like SAT3 and STAT5, are over-expressed in many cancers, such as renal cancer, and have a regulatory role in apoptosis inhibition and cell proliferation.^99,100 Kim and colleagues also showed that after 24 h of treatment with resveratrol, the reduction of the potential of mitochondrial membrane and induction of mitochondrial dysfunction occur through the suppression of IAP-1, IAP-2, Survivin, Bcl-2, and Bcl-xL and activation of caspase-3 leading to early and late apoptosis in RCC cells (Figure 3).⁹⁸ In addition, they found that resveratrol induced cell cycle development inhibition by increasing p21 and decreasing cyclin D1 and cyclin E expressions. Resveratrol also remarkably attenuated tumor invasion through suppression of cyclin D1, VEGF, and MMP-9, which are modulated through STAT3.^98,101–103 In in vitro study carried out by Zhao et al, the remarkable inhibitory effects of resveratrol at various doses (10-200 μM) on proliferation, migration, and metastasis of RCC cells, ACHN and A498 renal cell lines, were demonstrated by mediation of ERK1/2 and Akt signaling pathways.¹⁰⁴ From a more detailed view, resveratrol attenuated the expression of phosphorylated ERK1/2 and Akt protein levels, EMT markers (eg, vimentin and N-cadherin), tumor metastasis markers (MMP-2 and −9), and transcriptional repressors (snail), while elevated the levels of cell invasion suppressors, including tissue inhibitors of metalloproteinase 1 (TIMP1-1) and E-cadherin proteins in a time- and dose-dependent manner in both cell lines. They also expressed that treatment with resveratrol suppressed the production of filopodia, actin-rich plasma-membrane micro spikes,¹⁰⁵ which have a crucial role in cell migration.¹⁰⁴ Tian and co-workers designed another experimental study to find out the underlying molecular mechanism of antitumor properties of resveratrol in RCC in vitro and in vivo.¹⁰⁶ They observed that resveratrol at 100 μM (for 24 h) had the maximum antitumor effects on both 786-O and ACHN cell lines. They also stated that at this concentration, resveratrol significantly promoted apoptosis (by increasing Bax/Bcl-2 ratio), suppressed cell migration and invasion through downregulation of NLRP3 (nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3) inflammasome and its downstream genes in both cell lines compared to saline group. The in vivo results of this experiment implicated that resveratrol administration considerably repressed tumor growth since the 32th day of treatment, and RCC mice in the resveratrol group all survived on day 40 compared to the control (saline) group.¹⁰⁶ NLRP3 has been found to be extremely upregulated in RCC and has a pivotal role in caspase-1–associated maturation of the proinflammatory factors (eg, IL-18 and IL-1β) in tumor microenvironment.^107,108 Interestingly, a combination therapy with resveratrol and TNF-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) superfamily,¹⁰⁹ was inspected by Zeng et al in vitro and in vivo in 2020.¹¹⁰ TRAIL possesses cytotoxic effects on tumor cells and induces apoptosis selectively in cancer cells without harmful impacts on normal cells.¹¹¹ In order to evaluate the synergistic effects of TRAIL and resveratrol in vitro, Zeng et al found that resveratrol (100 μM) synergistically enhanced the apoptotic effects of TRAIL (200 ng/mL) on both OS-RC-2 and 786-0 cell lines. The analysis done with transmission electron microscopy provided evidence that the combination of TRAIL and resveratrol stimulates apoptosis and autophagy in RCC cells. Further assessments by the Western blot test indicated that the apoptosis in this occurrence is a caspase-dependent process with the involvement of caspase-3, caspase-8, and caspase-9. For an in vivo evaluation, they obtained Ad5/35-TRAIL, a fiber-modified replication-deficient adenovirus, and addressed that Ad5/35-TRAIL besides resveratrol remarkably suppressed tumor growth in nude mice.¹¹⁰ Other pre-clinical reports have also proposed a number of anticancer mechanisms of resveratrol against RCC, including suppression of the PI3K/AKT signaling pathway, increment of reactive oxygen species (ROS) as a trigger for apoptosis and autophagy, and promotion of histone acetylation.^97,112,113 In addition to resveratrol, the anti-RCC potential of the analogues of this polyphenol (ie, DMU-212 and HS-1793) has been exhibited through similar mechanisms.^112,114 Also, harnessing nano-based products of resveratrol to conquer its pharmacological challenges and elevate the therapeutic effectiveness has been suggested. Regarding this matter, a recent scientific project investigated the impacts of resveratrol nanoparticle-based therapy on RCC and focused on involved mechanisms in vitro.¹¹⁵ Finally, the authors explained that this nano-based formulation inhibits cancer cell invasion and migration in ACHN and A498 cells through down-regulation of MMP-2 and up-regulation of tissue inhibitor of metalloproteinases 2 (TIMP-2) in a dose-dependent way. Furthermore, resveratrol nanoparticles suppressed the p-ERK1/2 signaling pathway but had no impact on p-JNK and p-p38.¹¹⁵ Altogether, resveratrol nanoparticles suppressed the survival, invasion, and migration of RCC cells through inhibition of MMP-2 expression and ERK signaling pathway.¹¹⁵ It deems that resveratrol can positively affect RCC like PC and BC; moreover, using alternative formulations of this polyphenol, namely its analogues or nano-based products, can promote its efficiency against RCC.

Figure 3.

Anti-Cancer Mechanisms of Resveratrol Against Renal Cell Carcinoma.

Table 3.

In vitro and in vivo Studies of Resveratrol and Renal Cell Carcinoma.

Resveratrol or its analogues/nano-based formulations	Resveratrol dose/concentration	Target (s)	Effect/mechanisms (s)	Species	Cell line	Ref.
Resveratrol	25 and 50 μM	BGPa, MDM2A, GADD45, MDM2, MDM2E, RBP1, VDR, CSF1, IL-8, β-HCG, CRABP-II, TRAF-1, PAI-1, TNFAIP3, RelB, ATF3, HCK, GFRα2, IGFBP-5, HGF, CYP1B1, MUC1, and CXCR4	Stimulating the expression of genes associated with cell death and inhibiting cell growth	-	RCC54	¹¹⁶
Resveratrol	10-200 μM	Snail, Vimentin, N-cadherin, MMP-2 and -9, p-ERK1/2, p-Akt, TIMP-1, and E-cadherin	Repressing cell proliferation, migration, and invasion	-	A498 and ACHN	¹⁰⁴
Resveratrol	60 mg/kg and 25-100 μM	NLRP3, Bcl-2, Bax, IL-6, IL-1β, caspase-1 and -3, and E-cadherin	Repressing cell proliferation, migration, and invasion and stimulating apoptosis	Male nude mice	786-O and ACHN	¹⁰⁶
Resveratrol	0-50 μM	Akt, p-Akt, p-PI3K, PI3K, and Survivin	Attenuating chemoresistancy, stimulating apoptosis, and suppressing cell growth	-	Caki-1	⁹⁷
Resveratrol	0-100 μM	Bcl-2, Bax, AMPK, mTOR, p53, LC3, ATG5, and ATG7	Repressing cell migration and viability and inducing apoptosis and autophagy	-	Ketr-3 and HK-2	¹¹⁷
Resveratrol	10, 20, and 40 µM	Caspase 3, PARP, LC3B II, ERK, p38, and JNK	Repressing cell viability and stimulating apoptosis and autophagy	-	786-O	¹¹²
Resveratrol	0-50 μM	STAT3, STAT5, c-Src, JAK1, JAK2, SHP-2, PTPε, caspase-3, Survivin, Bcl-xL, Bcl-2, IAP-1, IAP-2, COX-2, MMP-9, and VEGF	Arresting cell cycle, stimulating apoptosis, and repressing colony formation and cell viability and invasion	-	786-O and Caki-1	¹¹⁸
Resveratrol	1, 2.5, and 5 mg/kg	Fas, FasL, IFN-γ, IL-6, IL-10, granzyme B, and perforin	Suppressing tumor growth, decreasing immune suppression, and suppressing angiogenesis	Female BALB/c mice	-	¹¹⁹
Resveratrol	0-62.5 μg/mL	MMP-2 and -9, acH3K9, acH3K14, acH4K12, acH4K5, and acH4K16	Repressing cell viability, migration, invasion and cell cycle	-	ACHN	¹¹³
Resveratrol	0-200 μM	COX-2, VEGF, AT1R, AngII, Bax, Bcl-2, and caspas-9	Repressing cell growth and stimulating apoptosis	-	A498 and ACHN	¹²⁰
Resveratrol	0-40 μM	VEGF	Suppressing cell proliferation and growth	-	786-0	¹⁰³
Cis-resveratrol and trans-resveratrol	0-100 μM	p53	Elevating cytotoxicity in cancer cells	-	SN12C and A498	¹²¹
Resveratrol analogue HS-1793	0-25 μM	Bcl-2, PML, Sp100, Daxx, and SUMO-1	Stimulating apoptosis, forming mature PML nuclear bodies, and decreasing cell viability	-	Caki-1	¹²²
Combination of TRAIL and resveratrol and combination of resveratrol and Ad5/35-TRAIL	200 mg/kg and 100 μM	Caspase-3, -8, and-9, XIAP, and PARP	Sensitizing to TRAIL-related death and suppressing tumor growth	Nude mice	OS-RC-2 and 786-0	¹²³
Combination of sorafenib and PEGylated resveratrol	200 μmol/kg and 10-640 mmol/L	HIF-lα, p-mTOR, p-Akt, p70S6k-4EBP-1, p-ERK, p-MEK, p-c-Raf, Bax, and Bcl-2	Repressing cell proliferation and migration and tumor growth and enhancing the proliferative capacity of inactivated splenic lymphocytes and the lymphocytes induced by lipopolysaccharide and concanavalin A	Male BABL/c mice	786-O	¹²⁴
Resveratrol nanoparticles	0-80 μM	MMP-2, TIMP-2, p-ERK1/2, p-JNK, and p-p38	Repressing cell viability, migration, and invasion	-	A498 and ACHN	¹⁹

Resveratrol and Testicular Cancer

Testicular cancer (TC) is another common neoplasm related to the urological system with considerable mortality and morbidity in men at young ages and is responsible for 10 000 death cases per year worldwide.¹²⁵ Some researchers have indicated the anti-neoplasm capacity of resveratrol in TC directly or indirectly. In this line, Chen et al inspected the effect of resveratrol as a phytoestrogen on the steroidogenesis of MA-10 cells, a cell line originating from mouse Leydig tumor cells.¹²⁶ They found that the incubation of MA-10 cells with 50 μM of this phytoestrogen leads to the suppression of progesterone release through the mRNA expression reduction of steroidogenic acute regulatory (StAR) induced by Cyclic AMP in this testicular murine tumor-related cell line.¹²⁶ Leydig cell tumor is an uncommon neoplasm emerging as a testicular mass with or without endocrine alterations.¹²⁷ In this testicular tumor, the secretion of steroid hormones, including progesterone, testosterone, and estrogen, has been approved as one of the pathogenic mechanisms.¹²⁸ StAR is an important regulatory protein with a pivotal function in conveying cholesterol into the mitochondria for steroidogenic activities and serves as a biomarker of Leydig cell tumors.¹²⁹ Another related effort has recently been made by Mitra and co-workers in vivo. They implicated the upregulation of the proteins pertained to testicular germ cell neoplasia in situ (GCNIS) and Akt cascade in mice tissues subjected to Pb(CH₃COO) ₂ (3 and 6 mg/kg) and cadmium chloride (0.25 and 0.5 mg/kg) compared with the health group.¹³⁰ On the other hand, resveratrol administration (20 mg/kg) could attenuate metal-conferred disruption of spermatogenesis, Akt cascade proteins (COX-2, NF-kB, and p-Akt) accompanied by GCNIS markers.¹³⁰ GCNIS is defined as a malignant testicular germ cell tumor precursor and expresses some markers comprising c-Kit and Oct 3/4.¹³¹ Also, Akt signaling has a substantial role in cellular activities, like apoptosis, proliferation, and protein synthesis, and its aberrant regulation has been detected in tumorigenesis.¹³⁰ The current evidence shows that resveratrol may target testicular cancer by regulating the secretion of steroid hormones and Akt signaling; however, more investigations are needed to approve this result and find other therapeutic mechanisms.

Resveratrol Limitations

Although resveratrol has several biological and therapeutic activities, there are some pharmacological limitations for this natural polyphenol that may affect its effectiveness in diseases. These limitations include its weak solubility in water, poor bioavailability, restricted stability, and a high rate of metabolization.⁹ An extensive metabolism in the intestine and liver has even yielded resveratrol bioavailability of less than 1%.¹³² However, bioavailability can be enhanced by various delivery systems such as chemical modification (to change chemical structure) and encapsulation approaches.^133–135

In addition to the mentioned pharmacological challenges, there has to be enough caution for using resveratrol mainly at inappropriate doses. Even though resveratrol can be considered a safe and well-tolerated compound, there is evidence indicating that it may be cytotoxic or harmful at high concentrations in vivo and in vitro.¹³⁶ Toxicological reports revealed that resveratrol administration at high doses in animal studies can cause nephrotoxicity.¹³⁷ In the work of Crowell et al¹³² to explore resveratrol cytotoxicity, rats received 0, 300, 1000, and 3000 mg/kg trans-resveratrol daily for 4 weeks. In evaluated animals, the most detrimental effects related to toxicity, such as decreased food consumption and body weight and increased creatinine, blood urea nitrogen (BUN), alanine aminotransferase, alkaline phosphatase, total bilirubin, and white cell levels, were observed following resveratrol usage at the dose of 3000 mg/kg.¹³⁸ In vitro results have also shown that this natural product can postpone the healing processes of gastric lesions and exacerbate cardiac damage induced by ischemic reperfusion at high concentrations.¹³⁶ Besides, scientific data pointed out the adverse influences of resveratrol after its intake at high doses in human studies.^139–141 As an example, in the investigation of Boocock et al,¹³⁴ it was addressed that out of 40 cases who were treated with 1 g resveratrol, 2 subjects experienced a slight increase in the levels of alanine aminotransferase and blood bilirubin.¹⁴⁰ Another research team declared three adverse events related to treatment with resveratrol, including erythematous rash, nasopharyngitis, and blood electrolyte changes, in 3 patients of 24 studied patients.¹³⁹ Biosafety of resveratrol also was tested in a clinical trial that was evaluated in 40 healthy volunteers. Intake of resveratrol in doses of 0.5, 1.0, 2.5, and 5.0 g/d in 29 days was found to be safe.¹⁴² Other researches indicated that high dose or long-term administration of this compound may lead to the suppression of cytochrome P450, a membrane-bound hemoprotein detoxifying drug, and thyroid disruption.^143–146 This evidence emphasizes the importance of resveratrol therapy at optimal doses and a suitable time framework for therapeutic purposes.

Resveratrol and Clinical Trials

Clinically, scientists also explored the anticancer impacts of resveratrol on some cancer, such as colorectal cancer, gastric cancer, breast cancer, and skin cancer (Table 4), and the results of some of these have not been published yet (https://clinicaltrials.gov). One of the published clinical papers regarding the anti-neoplasia effects of resveratrol and its metabolite on colorectal cancers has been undertaken by Patel and co-workers.¹⁴⁷ In this work, for 20 cases with histologically identified colorectal cancer, resveratrol at the dose of 0.5 or 1.0 g orally for 8 days was prescribed before surgical resection. Resveratrol along with its metabolites, comprising resveratrol disulfate, resveratrol sulfate glucuronide, resveratrol-4′-O-sulfate, resveratrol-3-O-sulfate, resveratrol-4′-O-glucuronide, and resveratrol-3-O-glucuronide, was detected in resected colorectal tissues by high-pressure liquid chromatography (HPLC) with mass spectrometric or UV identification. Resveratrol and one of its metabolites (resveratrol-3-O-glucuronide) were determined from tissues at maximal average levels (674 and 86.0 nmol/g, respectively). Moreover, resveratrol consumption decreased the proliferation rate of tumor cells by 5%.¹⁴⁷ Recently, a single-arm phase II study was conducted to examine the effectiveness of combination therapy with copper and resveratrol on the toxicity of chemotherapy based on docetaxel in the advanced stage of gastric cancer. For this purpose, 30 patients were pursued (between October 2019 and April 2021). Eventually, it was inferred that the administration of the combination of copper and resveratrol ameliorates chemotherapy-associated non-hematological toxicities, like diarrhea, vomiting, and hand-foot syndrome, in patients with gastric cancer at the advanced stage.¹⁴⁸ In another relevant project, 19 breast cancer patients consumed polyphenol-rich capsules containing the extracts of grape seed (53.85 mg), cocoa (161.5 mg), olive (161.5 mg), lemon (53.85 mg), orange (53.85 mg), pomegranate (161.5 mg), as well as trans-resveratrol (53.85 mg);¹⁴⁹ then, their metabolite profile was assessed. The patients were trained to take the supplements from the verified cancer diagnosis to the day of the initiation of surgery. Phenolic metabolites in healthy and malignant tissues were dominantly sulfated and glucuronidated. The results of this investigation manifested that these metabolites do not possess estrogenic/antiestrogenic or antiproliferative functions in breast cancer cells (MCF-7).¹⁴⁹ Regarding the clinical aspects of resveratrol therapy in urological cancers, some related clinical studies have been published.^150,151 In this regard, a clinical trial study was conducted by Paller et al on 14 patients with confirmed prostate adenocarcinoma. In the phase I of this work, patients with biochemically recurrent PC were allocated to elevating doses of a commercial product consisting of pulverized muscadine grape skin (MPX), in which a 500 mg capsule form is composed of polyphenols (ie, 4.4 μg trans-resveratrol, 9.2 μg quercetin, and 1.2 mg ellagic acid). The used doses of MPX in this study were 500, 1000, 2000, 3000, and 4000 mg. In the end, the authors observed the antitumor action of MPX, as evidenced by changes in prostate-specific antigen (PSA) doubling time.¹⁵⁰ A more updated study appraised the outcomes of phytotherapy by administrating two tablets (two times per day) of resveratrol (30 mg), broccoli sprout concentrate, green tea leaf concentrate, and turmeric (Curcuma longa) rhizome extract in biochemically recurrent PC cases.¹⁵¹ This double blind, randomized, placebo-controlled trial was performed to investigate 22 men with mentioned carcinoma for about 12 weeks. The involved patients were assigned to two groups of placebo and active (phytotherapy). The findings of performed tests indicated that phytotherapy-based intervention was well-tolerated. Moreover, the active group underwent an insignificant elevation in the log-slope of PSA, but the placebo group underwent no change in terms of the mentioned index (155). These data show that resveratrol can be effective in the clinic for fighting diverse cancers; however, concerning its effectiveness in urological cancers, more persuasive evidence is required.

Table 4.

Registered Clinical Studies Related to Resveratrol Therapy in Malignancies or Tumors. Reference: https://clinicaltrials.gov.

ID	Status	Malignancy/tumor	Used resveratrol	Enrolled subjects	Phase	Country
NCT01476592	Completed	Low grade gastrointestinal tumors	5 mg/day resveratrol orally	7	-	United States
NCT00256334	Completed	Colon cancer	20 and 80 mg/day resveratrol	11	Phase 1	United States
NCT03253913	Completed	Lymphangioleiomyomatosis	250 mg/day resveratrol for 8 weeks, then 500 mg/day for 8 weeks, and finally 500 mg twice a day for the last 8 weeks	25	Phase II	United States
NCT00433576	Completed	Colorectal cancer	-	20	Phase1	United States
NCT00920803	Completed	Colorectal Cancer	5 g micronized resveratrol (SRT501)	9	Phase1	United Kingdom
NCT03482401	Completed	Breast cancer	474 mg/day polyphenol supplement including resveratrol	40	-	Spain
NCT05306002	Active, not recruiting	Hereditary breast and ovarian cancer syndrome	Combination therapy with resveratrol and other natural compounds (eg, carotenoids, epigalactocatechin, curcumin etc)	34	-	Mexico
NCT05736224	Recruiting	Skin cancer	Sunscreen comprises bioadhesive nanoparticles (BNP) loaded with avobenzone and octocrylene plus some natural products including trans-resveratrol	30	Phase 1	United States

Conclusion

Urological cancers are among malignancies with high mortality and morbidity; thus, applying an efficient treatment against these serious illnesses is indispensable. The present scientific evidence reflects that resveratrol can be a good fighter against urological cancers through various cellular and molecular mechanisms. These mechanisms include repressing angiogenesis (by decreasing VEGF levels), modulating estrogen and androgen-related occurrences, epigenetic modifications (eg, downregulating oncogenic microRNAs and upregulating tumor suppressor microRNAs), attenuating EMT (by decreasing E-cadherin and Vimentin levels), arresting cell cycle (by downregulating CDK4, cyclin D1, and phosphorylated Rb and activating p21), stimulating apoptosis by elevating apoptosis-inducing agents (Bax and caspase-3 and −9), attenuating anti-apoptosis agents (survivin, Bcl-xL, and Bcl-2), degrading PARP, suppressing inflammatory-associated factors (eg, IL-6 and NLRP3), and attenuating drug resistance-related proteins (ie, Bcl-2, GST, LRP, and MRP1). Despite this, the utilization of resveratrol is accompanied by low bioavailability which is necessitated by poor solubility in water and high rate of metabolism in the intestine and liver. It has to be mentioned that to reach the expected therapeutic outcomes of this polyphenol, optimal doses and appropriate timelines are necessary to avoid possible toxic influences. Several researchers suggest that analogues and nanoformulations of resveratrol can be more efficient against these cancers compared with pure resveratrol by overcoming its pharmacological challenges such as low bioavailability and exerting similar therapeutic mechanisms. However, more preclinical and clinical investigations are still neededto confirm promising findings.

Abbreviation

LC3, Light chain 3; ATG, Autophagy related; TRAP, Transgenic Rat for Adenocarcinoma of Prostate; ARV7, Androgen receptor splice variant 7; PCAT29, Prostate cancer associated transcript 29; PDCD4, Programmed cell death protein 4; ANO1, Anoctamin1; DDX5, DEAD (Asp-Glu-Ala-Asp) box helicase 5; TRAF6, TNF-receptor associated factor 6; STIM1, Stromal interaction molecule 1; BGP, Biliary glycoprotein; MDM2A, Mouse double minute 2-A; GADD45, Growth arrest and DNA-damage-inducible protein 45; RBP1, Retinoblastoma binding protein 1 isoform I; VDR, Vitamin D receptor; CSF1, Granulocyte-macrophage colony-stimulating factor; IL, Interleukin; HCG, Human chorionic gonadotropin; CRABP-II, Cellular retinoic acid binding protein-II; TRAF, Tumor necrosis factor receptor; PAI-1, Plasminogen activator inhibitor-1; TNFAIP3, Tumor necrosis factor α inducible protein 3; RelB, V-rel reticuloendoiheliosis viral oncogene homolog B; ATF3, Activating transcription factor 3; HCK, Hemopoietic cell protein-tyrosine kinase, GFRα2, GDNF family receptor α 2; IGFBP-5, Insulin-like growth factor binding protein 5; HGF, Hepatocyte growth factor; CYP1B1, Cytochrome P450 1B1; MUC1, Mucin 1; CXCR4, Chemokine (C-X-C motif) receptor 4; ERK, Extracellular-signal-regulated kinase; TIMP, Tissue inhibitor of metalloproteinase; Bax, Bcl-2 associated X; PI3K, Phosphoinositide 3-kinase; AMPK, AMP-activated protein kinase; mTOR, Mammalian target of rapamycin; JNK, c-Jun N-terminal Kinase; JAK1, Janus kinase 1; SHP-2, SH2-containing protein tyrosine phosphatase-2; PTPε, Protein tyrosine phosphatase epsilon; IAP-1, Inhibitor of apoptosis protein-1; COX-2, Cyclooxygenase-2; Sirt1, Sirtuin 1; HIF-lα, Hypoxia inducible factor-1α; MEK, MAPK/ERK kinase; XIAP, X-linked inhibitor of apoptosis protein; PML, Promyelocytic leukemia; SUMO-1, Small ubiquitin like modifier 1; Daxx, Death domain-associated protein; AT1R, AngII type 1 receptor; AngII, Angiotensin II; acH3K, Acetylated histone H3 lysine; BCHE, Butyrylcholinesterase; FRAP, FKBP-12-rapamycin associated protein; PIK3R3, Phosphoinositide-3-kinase regulatory subunit 3; IGF-1R, Insulin-like growth factor 1 receptor; STK39, Serine/threonine kinase 39; CDKN1A, Cyclin dependent kinase inhibitor 1A; MDR-1, Multidrug resistance mutation 1; MRP-1, Multidrug resistance protein 1; ABCG2, ATP-binding cassette super-family G member 2; AR, Androgen receptor; CDK2, Cyclin-dependent kinase 2; p-γ-H2AX, Phosphorylated histone 2A family member X; CHK2, Checkpoint kinase 2; ATM, Ataxia telangiectasia mutated; SOX2, SRY (sex determining region Y)-box 2; OCT4, Octamer-binding transcription factor 4; DCLK1, Doublecortin like kinase 1; VE-cadherin, Vascular endothelial cadherin; EphA2, Erythropoietin-producing hepatocellular receptor A2; Gk11, Glandular kallikrein 11; DR4, Death receptor 4; Gli1, Glioma-associated oncogene-1; FasL, Fas ligand; IFN-γ, Interferon gamma; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells; mTORC1, Mammalian target of rapamycin complex 1; GRP78, Glucose-regulating protein 78; CHOP, C/-EBP homologous protein; NO, Nitric oxide; PGE₂, Prostaglandin E₂; RB, Retinoblastoma; MAPK, Mitogen-activated protein kinase; FGF-2, Fibroblast growth factor 2; GST, Glutathione S-transferase; LRP, Lung resistance protein; DNMT1, DNA cytosine-5-methyltransferase 1; RASSF1A, Ras association domain family protein1 isoform A; HOXB3, Homo sapiens homeobox B3; PLK1, Polo-like kinase 1; CDH1, Cadherin 1; CTNNB1P1, Catenin beta interacting protein 1; PRAS40, Proline-rich Akt substrate of 40 kDa; EMT, Epithelial-mesenchymal transition; VGSC, Voltage-gated NaC channel; FBS, Fetal bovine serum.

Footnotes

Acknowledgment

Figures were created with BioRender.com

ORCID iD

Fatemeh Rezaei-Tazangi

Ethics Approval and Consent to Participate

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Author Contributions

R.A., M.R., A.J., A.H., PM, A.B., P.G., H.F. and F.R. wrote the main manuscript text and A.A., G.F. and N.B. prepared figures. All authors reviewed the manuscript.

Funding

Those authors are preparing the article in their personal capacity. This work was not financially supported.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of Data and Materials

Data available on request from the authors.

References

Saad

Clothier

. Urological disorders in children that progress to chronic kidney failure. Medicine (Baltimore). 2023. doi:10.1097/MD.0000000000033981

Moon

Choi

Kim

. Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocr Relat Cancer. 2016;23(10):R455-R467. doi:10.1530/ERC-16-0294

Zhang

Wang

Zhang

, et al. The function and mechanisms of action of circular RNAs in urologic cancer. Mol Cancer. 2023;22(1):61. doi:10.1186/s12943-023-01754-9

Chen

Zhang

Maskey

, et al. Urological cancer organoids, patients’ avatars for precision medicine: past, present and future. Cell Biosci. 2022;12(1):132. doi:10.1186/s13578-022-00863-z

Pourhanifeh

Hosseinzadeh

Juybari

Mehrzadi

. Melatonin and urological cancers: a new therapeutic approach. Cancer Cell Int. 2020;20(1):11. doi:10.1186/s12935-020-01390-5

Wigner

Bijak

Saluk-Bijak

. The green anti-cancer weapon. The role of natural compounds in bladder cancer treatment. Int J Mol Sci. 2021;22(15):7787. doi:10.3390/ijms22157787

Mao

Wang

Chen

. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. J Exp Clin Cancer Res. 2021;40(1):13. doi:10.1186/s13046-020-01788-6

Silk

Reich

Sinha

Chawla

Geary

Zhang

. The effects of resveratrol on prostate cancer through targeting the tumor microenvironment. J Xenobiot. 2021;11(1):16-32. doi:10.4081/xeno.2021.1015

Rezaei-Tazangi

Roghani-Shahraki

Khorsand Ghaffari

, et al. The therapeutic potential of common herbal and nano-based herbal formulations against ovarian cancer: new insight into the current evidence. Pharmaceuticals (Basel). 2021;14(12):1315. doi:10.3390/ph14121315

10.

Asiamah

Obiri

Tamekloe

Armah

Borquaye

. Applications of molecular docking in natural products-based drug discovery. Sci Afr. 2023:e01593. doi:10.1016/j.sciaf.2023.e01593

11.

Xiao

Zhu

Feng

, et al. A review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy. Front Pharmacol. 2019;9:1534. doi:10.3389/fphar.2018.01534

12.

Rezaei-Tazangi

Mirhosseini

Fathi

Roghani-Shahraki

Arefnezhad

Vasei

. Herbal and nano-based herbal medicine: new insights into their therapeutic aspects against periodontitis. Avicenna J Phytomed. 2024;14(4):430-444.

13.

Ren

Shen

Lin

, et al. Mechanistic analysis of resveratrol in cardiac hypertrophy by network pharmacology and animal experiments. Mol Med Rep. 2022;26(5):1-11. doi:10.3892/mmr.2022.12791

14.

Zeng

Wang

Huang

, et al. Resveratrol inhibits neural apoptosis and regulates RAX/P-PKR expression in retina of diabetic rats. Nutr Neurosci. 2022;25(12):2560-2569. doi:10.1080/1028415X.2021.1886259

15.

Hoca

Becer

Vatansever

. The role of resveratrol in diabetes and obesity associated with insulin resistance. Arch Physiol Biochem. 2023;129(2):555-561. doi:10.1080/13813455.2022.2091463

16.

Novakovic

Rajkovic

Gostimirovic

Gojkovic-Bukarica

Radunovic

. Resveratrol and reproductive health. Life (Basel). 2022;12(2):294. doi:10.3390/life12020294

17.

Badawi

. Resveratrol used as nanotherapeutic: a promising additional therapeutic tool against hormone-sensitive, hormone-insensitive and resistant prostate cancer. Am J Clin Exp Urol. 2023;11(1):1-12. doi:10.5455/ajceu.20230123031507

18.

Almeida

Melo

Lima

APB

Branquinho

da Silva

. Resveratrol induces the production of reactive oxygen species, interferes with the cell cycle, and inhibits the cell migration of bladder tumour cells with different TP53 status. Nat Prod Res. 2022;36(11):2912-2917. doi:10.1080/14786419.2020.1866182

19.

Zhu

Dong

Liu

. Resveratrol nanoparticles suppress migration and invasion of renal cell carcinoma cells by inhibiting matrix metalloproteinase 2 expression and extracellular signal-regulated kinase pathway. J Biomed Nanotechnol. 2022;18(4):1001-1008. doi:10.1166/jbn.2022.3165

20.

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

21.

Crowley

Mihalopoulos

Gaglani

, et al. Prostate cancer in transgender women: considerations for screening, diagnosis and management. Br J Cancer. 2023;128(2):177-189. doi:10.1038/s41416-022-02034-1

22.

Muralidhar

Potluri

Jaiswal

McNeel

. Targeted radiation and immune therapies—advances and opportunities for the treatment of prostate cancer. Pharmaceutics. 2023;15(1):252. doi:10.3390/pharmaceutics15010252

23.

Lourenço

Vale

. Pharmacological efficacy of repurposing drugs in the treatment of prostate cancer. Int J Mol Sci. 2023;24(4):4154. doi:10.3390/ijms24044154

24.

Wang

, et al. Resveratrol inhibits TRAF6/PTCH/SMO signal and regulates prostate cancer progression. Cytotechnology. 2022;74(5):549-558. doi:10.1007/s10616-022-00501-8

25.

Aktepe

Yukselten

. Induction of apoptosis in human hormone-refractory prostate cancer cell lines by using resveratrol in combination with AT-101. Andrologia. 2022;54(1):e14267. doi:10.1111/and.14267

26.

van Die

Williams

Emery

, et al. A placebo-controlled double-blinded randomized pilot study of combination phytotherapy in biochemically recurrent prostate cancer. Prostate. 2017;77(7):765-775. doi:10.1002/pros.23309

27.

Paller

Rudek

Zhou

, et al. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: safety, tolerability, and dose determination. Prostate. 2015;75(14):1518-1525. doi:10.1002/pros.23048

28.

Wang

Hudson

Wang

, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008;29(10):2001-2010. doi:10.1093/carcin/bgn201

29.

El-Benhawy

Morsi

Fahmy

Soula

Khalil

Arab

. Role of resveratrol as radiosensitizer by targeting cancer stem cells in radioresistant prostate cancer cells (PC-3). Asian Pac J Cancer Prev. 2021;22(12):3823-3837. doi:10.31557/APJCP.2021.22.12.3823

30.

Fan

Liu

Pan

Lin

. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol Oncol. 2012. doi:10.1016/j.urolonc.2012.09.006

31.

Rashid

Liu

Sanli

, et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, akt and mTOR pathways. Radiat Oncol. 2011;6:49. doi:10.1186/1748-717X-6-49

32.

Dhar

Hicks

Levenson

. Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res. 2011;55(8):1219-1229. doi:10.1002/mnfr.201000655

33.

Dias

Rimando

, et al. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate. 2013;73(11):1135-1146. doi:10.1002/pros.22695

34.

Singh

Lillard

Jr Singh

. Reversal of drug resistance by planetary ball milled nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018;427:49-62. doi:10.1016/j.canlet.2018.04.027

35.

Chaudhary

Subramaniam

Khan

, et al. Encapsulation and controlled release of resveratrol within functionalized mesoporous silica nanoparticles for prostate cancer therapy. Front Bioeng Biotechnol. 2019;7:225. doi:10.3389/fbioe.2019.00225

36.

Kuwajerwala

Cifuentes

Gautam

Menon

Barrack

Reddy

. Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis. Cancer Res. 2002;62(9):2488-2492.

37.

El-Benhawy

Morsi

Fahmy

, et al. Role of resveratrol as radiosensitizer by targeting cancer stem cells in radioresistant prostate cancer cells (PC-3). Asian Pac J Cancer Prev. 2021;22(12):3823-3837. doi:10.31557/APJCP.2021.22.12.3823

38.

Han

Lee

. Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells. Sci Rep. 2022;12(1):20125. doi:10.1038/s41598-022-24637-8

39.

Harper

Patel

Wang

Arabshahi

Eltoum

Lamartiniere

. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis. 2007;28(9):1946-1953. doi:10.1093/carcin/bgm132

40.

Seeni

Takahashi

Takeshita

, et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev. 2008;9(1):7-14.

41.

Benitez

Pozo-Guisado

Alvarez-Barrientos

Fernandez-Salguero

Castellón

. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer–derived cell lines. J Androl. 2007;28(2):282-293.

42.

Chen

Ganapathy

Singh

Shankar

Srivastava

. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One. 2010;5(12):e15288. doi:10.1371/journal.pone.0015288

43.

Chong

Wang

, et al. A novel anti-cancer effect of resveratrol: reversal of epithelial-mesenchymal transition in prostate cancer cells. Mol Med Rep. 2014;10(4):1717-1724.

44.

Fang

DeMarco

Nicholl

. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci. 2012;103(6):1090-1098.

45.

Khusbu

Zhou

Roy

Chen

F-Z

Cao

Chen

H-C

. Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration. Int J Biochem Cell Biol. 2020;118:105644. doi:10.1016/j.biocel.2019.105644

46.

Hudson

Hartle

Hursting

, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res. 2007;67(17):8396-8405.

47.

Aameri

Sheth

Alanisi

, et al. Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer. Reversal by Resveratrol. PLoS One. 2017;12(5):e0177198. doi:10.1371/journal.pone.0177198

48.

Fonseca

Moradi

Maddalena

Ferreira-Tollstadius

Selim

Stuart

. Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1. Oncol Lett. 2019;17(1):697-705.

49.

Wilson

Cavero

Tong

, et al. Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. Oncotarget. 2017;8(33):54683.

50.

Kai

Levenson

. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res. 2011;31(10):3323-3330.

51.

Taniguchi

Iizumi

Watanabe

, et al. Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer. Cell Death Dis. 2016;7(5):e2211. doi:10.1038/cddis.2016.96

52.

Tian

Lin

, et al. Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling pathway in LNCaP prostate cancer cells. Oncol Lett. 2020;20(5):1-12.

53.

Cheng

Chin

, et al. Resveratrol induces sumoylated COX-2-dependent anti-proliferation in human prostate cancer LNCaP cells. Food Chem Toxicol. 2018;112(14):67-75.

54.

Selvaraj

Sun

Sukumaran

Singh

. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway. Mol Carcinog. 2016;55(5):818-831.

55.

Kim

Hossain

Kim

, et al. A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells. Int J Oncol. 2013;43(6):1915-1924.

56.

Chen

Lien

Kao

, et al. Sensitization of radioresistant prostate cancer cells by resveratrol isolated from Arachis hypogaea stems. PLoS One. 2017;12(1):e0169204. doi:10.1371/journal.pone.0169204

57.

Narayanan

Nargi

Randolph

Narayanan

. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer. 2009;125(1):1-8.

58.

Nassir

Shahzad

Ibrahim

Ahmad

Ain

. Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J. 2018;26(6):876-885.

59.

Zhang

Lin

Chen

, et al. Co-delivery of docetaxel and resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer. Eur J Pharm Sci. 2022;174:106199. doi:10.1016/j.ejps.2022.106199

60.

Singh

Lillard

Jr Singh

. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018;427:49-62. doi:10.1016/j.canlet.2018.04.032

61.

Anwar

Altaf

Imran

, et al. Anti-cancer perspectives of resveratrol: a comprehensive review. Food Agric Immunol. 2023;34(1):2265686. doi:10.1080/09540105.2023.2265686

62.

Berman

Motechin

Wiesenfeld

Holz

. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1(1):35. doi:10.1038/s41698-017-0038-6

63.

El-Mahdy

Elsakka

El-Husseiny

, et al. miRNAs role in bladder cancer pathogenesis and targeted therapy: signaling pathways interplay-A review. Pathol Res Pract. 2023;xx(x):154316. doi:10.1016/j.prp.2023.154316

64.

Zucchi

Claps

Pastore

, et al. Focus on the use of resveratrol in bladder cancer. Int J Mol Sci. 2023;24(5):4562. doi:10.3390/ijms24054562

65.

Møller

. 2023. Treatment and survival of patients with muscle-invasive bladder cancer: A nationwide register-based approach.

66.

Ashrafizadeh

Zarrabi

Karimi-Maleh

, et al. (Nano) platforms in bladder cancer therapy: challenges and opportunities. Bioeng Transl Med. 2023;8(1):e10353. doi:10.1002/btm2.10353

67.

Khan

Quispe

Javed

, et al. Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. Cancer Cell Int. 2020;20:1-19. doi:10.1186/s12935-020-01294-x

68.

Wang

Meng

Xie

Zhang

. Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep. 2017;15(3):1179-1187. doi:10.3892/mmr.2016.6041

69.

Nikmohammadi

Sarbakhsh

Goudarzi

, et al. The effect of B-cell lymphoma 2 and BCL2-associated X polymorphisms on the survival of acute lymphoblastic leukemia patients: application of frailty survival models. Iran J Public Health. 2022;51(4):895-905.

70.

Pugazhendhi

Dhanarani

Shankar

, et al. Electrophoretic pattern of glutathione S-transferase (GST) in antibiotic resistance Gram-positive bacteria from poultry litter. Microb Pathog. 2017;110:285-290. doi:10.1016/j.micpath.2017.07.048

71.

Scheffer

Schroeijers

Izquierdo

Wiemer

Scheper

. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol. 2000;12(6):550-556.

72.

Cullen

Newkirk

Schumaker

Aldosari

Rone

Haddad

. Glutathione S-transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 2003;63(23):8097-8102.

73.

Sakamoto

Kondo

Kawasaki

, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 2001;14(4):305-315.

74.

Kellner

Sehested

Jensen

Gieseler

Rudolph

. Culprit and victim–DNA topoisomerase II. Lancet Oncol. 2002;3(4):235-243.

75.

Almeida

Guerra

CCC

Assis

, et al. Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. Environ Mol Mutagen. 2019;60(8):740-751. doi:10.1002/em.22291

76.

Baylin

Herman

. DNA Hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168-174.

77.

Palakurthy

Wajapeyee

Santra

, et al. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol Cell. 2009;36(2):219-230. doi:10.1016/j.molcel.2009.08.026

78.

Bai

Mao

Qin

, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010;101(2):488-493. doi:10.1111/j.1349-7006.2009.01420.x

79.

, et al. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One. 2014;9(2):e89806. doi:10.1371/journal.pone.0089806

80.

Yang

Zhang

, et al. Metabolic profile and structure–activity relationship of resveratrol and its analogs in human bladder cancer cells. Cancer Manag Res. 2019;11:4631-4642. doi:10.2147/CMAR.S214810

81.

Stocco

Toledo

Salvador

Paulo

Koyama

Toloi

MRT

. Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas. 2012;72(1):72-78. doi:10.1016/j.maturitas.2012.02.013

82.

Zhou

Ding

. Resveratrol induces apoptosis of bladder cancer cells via miR-21 regulation of the Akt/Bcl-2 signaling pathway. Mol Med Rep. 2014;9(4):1467-1473. doi:10.3892/mmr.2014.1957

83.

Bai

Yang

Zhang

, et al. Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol Med Rep. 2017;15(2):885-889. doi:10.3892/mmr.2016.6006

84.

Lin

Huo

Zhang

Jin

. Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol. 2012;19(8):757-764. doi:10.1111/j.1442-2042.2012.03077.x

85.

Alayev

Salamon

Schwartz

Berman

Wiener

Holz

. Combination of rapamycin and resveratrol for treatment of bladder cancer. J Cell Physiol. 2017;232(2):436-446. doi:10.1002/jcp.25404

86.

Soares

LBM

Lima

APB

Melo

Almeida

de Medeiros Teixeira

da Silva

. Additive effects of resveratrol and doxorubicin on bladder cancer cells. Anti-Cancer Drugs. 2022;33(1):e389-e397. doi:10.1097/CAD.0000000000001314

87.

Rinaldi

Maurizi

Forte

, et al. Resveratrol-loaded nanoemulsions: in vitro activity on human T24 bladder cancer cells. Nanomaterials. 2021;11(6):1569. doi:10.3390/nano11061569

88.

Mathur

Shafie

Alharbi

, et al. Genome-wide analysis of kidney renal cell carcinoma: exploring differentially expressed genes for diagnostic and therapeutic targets. OMICS. 2023;27(8):393-401. doi:10.1089/omi.2023.0028

89.

Chung

Kang

Lee

, et al. Single omental metastasis of renal cell carcinoma after radical nephrectomy: a case report. World J Clin Cases. 2023;11(25):5994-5999. doi:10.12998/wjcc.v11.i25.5994

90.

Feng

Cao

Ouyang

, et al. Prevalence of germline mutations in cancer susceptibility genes in Chinese patients with renal cell carcinoma. Transl Androl Urol. 2023;12(2):308-317. doi:10.21037/tau-22-755

91.

Linehan

. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22(11):2089-2100. doi:10.1101/gr.127316.111

92.

Elballal

Sallam

AA-M

Elesawy

, et al. miRNAs as potential game-changers in renal cell carcinoma: future clinical and medicinal uses. Pathol Res Pract. 2023;xx(xx):154439. doi:10.1016/j.prp.2023.154439

93.

Pal

Madamsetty

Rachamala

Dutta

Wang

Mukhopadhyay

. Abstract B026: combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma. Cancer Res. 2023;83(16_Supplement):B026-B026. doi:10.1158/1538-7445.am2023-b026

94.

Kang

Wang

Shen

, et al. PDIA4 Confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma. Cell Death Dis. 2023;14(3):193. doi:10.1038/s41419-023-05705-3

95.

Oladejo

Nguyen

Wood

. CD105 In the progression and therapy of renal cell carcinoma. Cancer Lett. 2023;xx(xx):216327. doi:10.1016/j.canlet.2023.216327

96.

Kabel

Atef

Estfanous

. Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma. Biomed Pharmacother. 2018;97:667-674. doi:10.1016/j.biopha.2017.11.121

97.

Ying-Jie

Ling-Wei

Min

, et al. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. Front Biosci (Landmark Ed). 2019;24(8):1452-1461. doi:10.2741/4774

98.

Kim

Baek

Shim

Ahn

. Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. BMC Nephrol. 2016;17:19. doi:10.1186/s12882-016-0243-1

99.

Priceman

Xin

, et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 2013;8(12):e81657. doi:10.1371/journal.pone.0081657

100.

Subramaniam

Shanmugam

Ong

, et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 2013;170(4):807-821. doi:10.1111/bph.12247

101.

Drobnjak

Osman

Scher

Fazzari

Cordon-Cardo

. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6(5):1891-1895.

102.

Weidner

Carroll

Flax

Blumenfeld

Folkman

. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143(2):401-409.

103.

Yang

Zhang

Zhu

. Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells. Mol Med Rep. 2011;4(5):981-983. doi:10.3892/mmr.2011.502

104.

Zhao

Tang

Zeng

Liu

. Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. Biomed Pharmacother. 2018;98:36-44. doi:10.1016/j.biopha.2017.12.088

105.

Mattila

Lappalainen

. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9(6):446-454. doi:10.1038/nrm2406

106.

Tian

Zhang

, et al. Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma. J Nutr Biochem. 2020;85:108489. doi:10.1016/j.jnutbio.2020.108489

107.

McGeough

Wree

Inzaugarat

, et al. TNF Regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017;127(12):4488-4497. doi:10.1172/JCI92867

108.

Wang

Ruan

, et al. LXRα promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma. Cell Death Dis. 2019;10(3):159. doi:10.1038/s41419-019-1467-y

109.

Wiley

Schooley

Smolak

, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673-682. doi:10.1016/1074-7613(95)90137-6

110.

Zeng

Shi

, et al. Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma. Cancer Gene Ther. 2020;27(7):619-623. doi:10.1038/s41417-020-0183-6

111.

Kim

Ahn

Lee

Hong

Lee

. Anti-cancer effect of neural stem cells transfected with carboxylesterase and sTRAIL genes in animals with brain lesions of lung cancer. Pharmaceuticals (Basel). 2023;16(8):1156. doi:10.3390/ph16081156

112.

Yao

Fan

. Autophagy suppresses resveratrol-induced apoptosis in renal cell carcinoma 786-O cells. Oncol Lett. 2020;19(4):3269-3277. doi:10.3892/ol.2020.11403

113.

Dai

Chen

Wang

Lin

. Resveratrol inhibits ACHN cells via regulation of histone acetylation. Pharm Biol. 2020;58(1):231-238. doi:10.1080/13880209.2019.1711212

114.

Penthala

Thakkar

Crooks

. Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorg Med Chem Lett. 2015;25(14):2763-2767. doi:10.1016/j.bmcl.2015.05.008

115.

Zhu

Dong

Liu

116.

Shi

Liou

Sadhukhan

, et al. Effects of resveratrol on gene expression in renal cell carcinoma. Cancer Biol Ther. 2004;3(9):882-888. doi:10.4161/cbt.3.9.1037

117.

Liu

Fang

Han

Cheng

Zhang

. Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP-activated protein kinase/mammalian target of rapamycin autophagy signaling pathway. Mol Med Rep. 2018;17(1):502-508. doi:10.3892/mmr.2017.7978

118.

Kim

Baek

Shim

Ahn

119.

Chen

Yang

Liao

Xiong

. Modification of antitumor immunity and tumor microenvironment by resveratrol in mouse renal tumor model. Cell Biochem Biophys. 2015;72(2):617-625. doi:10.1007/s12013-015-0601-8

120.

Qiu

Chen

Liu

Tan

Liu

. Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism. Oncol Lett. 2017;13(2):613-620. doi:10.3892/ol.2016.5376

121.

Leischner

Burkard

Michel

, et al. Comparative analysis of the antitumor activity of cis- and trans-resveratrol in human cancer cells with different p53 status. Molecules. 2021;26(18):5586. doi:10.3390/molecules26185586

122.

Jeong

Lee

Jeong

, et al. A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol. 2009;35(6):1353-1360. doi:10.3892/ijo_00000570

123.

Zeng

Shi

, et al. Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma. Cancer Gene Ther. 2020;27(7-8):619-623. doi:10.1038/s41417-020-0183-6

124.

Wang

, et al. Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways. Heliyon. 2023;9(8):e18332. doi:10.1016/j.heliyon.2023.e18332

125.

Arefnezhad

Goleij

Heydari

Rezaei-Tazangi

Motedayyen

. Ameliorating effects of curcumin on testicular cancer. Andrologia. 2023;55(3):e14249. doi:10.1111/and.14249

126.

Chen

Nagpal

Stocco

Lin

. Effects of genistein, resveratrol, and quercetin on steroidogenesis and proliferation of MA-10 mouse Leydig tumor cells. J Endocrinol. 2007;192(3):527-537. doi:10.1677/JOE-06-0296

127.

Zhu

Luan

. Management of testicular Leydig cell tumor: a case report. Med (Baltimore). 2018;97(25):e11158. doi:10.1097/MD.0000000000011158

128.

Kong

Tian

, et al. Leydig cell tumor of a testis with azoospermia: a case report and literature review. Med (Baltimore). 2020;99(36):e22085. doi:10.1097/MD.0000000000022085

129.

Bassi

Sidhu

Mishra

. The intracellular cholesterol pool in steroidogenic cells plays a role in basal steroidogenesis. J Steroid Biochem Mol Biol. 2022;220:106099. doi:10.1016/j.jsbmb.2022.106099

130.

Mitra

Patra

Saha

, et al. Sub-chronic cadmium and lead compound exposure induces reproductive toxicity and development of testicular germ cell neoplasia in situ in murine model: attenuative effects of resveratrol. J Biochem Mol Toxicol. 2022;36(7):e23058. doi:10.1002/jbt.23058

131.

Akyüz

Topaktaş

Ürkmez

Koca

. Öztürk Mİ. Evaluation of germ-cell neoplasia in situ entity in testicular tumors. Turk J Urol. 2019;45(6):418-424. doi:10.5152/tud.2019.19002

132.

Walle

. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9-15. doi:10.1111/j.1749-6632.2010.05842.x

133.

Aqil

Munagala

Jeyabalan

Vadhanam

. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013;334(1):133-141. doi:10.1016/j.canlet.2012.11.028

134.

Lin

Zhao

, et al. Bioaccessibility and bioavailability of phytochemicals: influencing factors, improvements, and evaluations. Food Hydrocoll. 2023;135:108165. doi:10.1016/j.foodhyd.2022.108165

135.

Williamson

. Bioavailability of food polyphenols: Current state of knowledge. Annu Rev Food Sci Technol. 2025;16. doi:10.1146/annurev-food-041822-051304

136.

Calabrese

Mattson

Calabrese

. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol. 2010;29(12):980-1015. doi:10.1177/0960327110380704

137.

Cottart

Nivet-Antoine

Laguillier-Morizot

Beaudeux

. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010;54(1):7-16. doi:10.1002/mnfr.200900437

138.

Crowell

Korytko

Morrissey

Booth

Levine

. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82(2):614-619. doi:10.1093/toxsci/kfh320

139.

Vaz-da-Silva

Loureiro

Falcao

, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46(11):564-570. doi:10.5414/cpp46564

140.

Boocock

Faust

Patel

, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246-1252. doi:10.1158/1055-9965.EPI-07-0011

141.

Almeida

Vaz-da-Silva

Falcão

, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl 1):S7-S15. doi:10.1002/mnfr.200800363

142.

Singh

Verma

, et al. Health benefits of resveratrol: evidence from clinical studies. Med Res Rev. 2019;39(5):1851-1891. doi:10.1002/med.21597

143.

Zhao

, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23):12593. doi:10.3390/ijms222312593

144.

Detampel

Beck

Krähenbühl

Huwyler

. Drug interaction potential of resveratrol. Drug Metab Rev. 2012;44(3):253-265. doi:10.3109/03602532.2012.694851

145.

Giuliani

Iezzi

Ciolli

, et al. Resveratrol has anti-thyroid effects both in vitro and in vivo. Food Chem Toxicol. 2017;107(Pt A):237-247. doi:10.1016/j.fct.2017.07.011

146.

Giuliani

Bucci

Di Santo

, et al. Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells. PLoS One. 2014;9(9):e107936. doi:10.1371/journal.pone.0107936

147.

Patel

Brown

Jones

, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70(19):7392-7399. doi:10.1158/0008-5472.CAN-10-1120

148.

Ostwal

Ramaswamy

Bhargava

, et al. A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study). Med Oncol. 2022;40(1):17. doi:10.1007/s12032-022-01665-w

149.

Ávila-Gálvez

MÁ

García-Villalba

Martínez-Díaz

, et al. Metabolic profiling of dietary polyphenols and methylxanthines in normal and malignant mammary tissues from breast cancer patients. Mol Nutr Food Res. 2019;63(9):e1801239. doi:10.1002/mnfr.201801239

150.

Paller

Rudek

Zhou

151.

van Die

Williams

Emery

, et al. A placebo-controlled double-blinded randomized pilot study of combination phytotherapy in biochemically recurrent prostate cancer. Prostate. 2017;77(7):765-775. doi:10.1002/pros.23303

Resveratrol and Urological Cancers: Taking Stock of the Current Evidence

Abstract

Keywords

Introduction

Search Strategy

Resveratrol and Prostate Cancer

Resveratrol and Bladder Cancer

Resveratrol and Renal Cell Carcinoma

Resveratrol and Testicular Cancer

Resveratrol Limitations

Resveratrol and Clinical Trials

Conclusion

Abbreviation

Footnotes

Acknowledgment

ORCID iD

Ethics Approval and Consent to Participate

Author Contributions

Funding

Declaration of Conflicting Interests

Availability of Data and Materials

References